Cleveland (Tas.) notes

NovoSeven: Cleveland Clinic Guidelines

In This Issue: • NovoSeven • Therapeutic Interchanges Introduction: Recombinant human activated Factor VII (rFVIIa), or NovoSeven, is a hemostatic agent which is structurally similar to human plasma-derived coagulation Factor VIIa. Recombinant FVIIa is currently licensed by the US Food and Drug Administration (FDA) in patients with hemophilia A or B with inhibitors to Factor VIII or Factor IX o...

The Cleveland Clinic Foundation

1.) Pregabalin (Lyrica): Pregabalin is FDA-approved for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, and as an adjunct therapy for patients with partial-onset seizures. Although it is a structural analogue of gamma-aminobutyric acid (GABA), its exact mechanism is unknown. Common adverse effects associated with pregabalin use include ...

Art - Cleveland (J)

ALS is a progressive neurodegenerative disease occurring in middle to late life and characterized by the loss of large motor neurons of the spinal cord, brain stem and motor cortex. Dysfunction and death of these motor neurons causes muscle weakness and atrophy leading to paralysis and death in 3–5 years1. Approximately 10% of ALS cases are inherited in an autosomal dominant fashion. An estimat...

The aftermath of Cleveland.

The Cleveland Clinic Way

The global healthcare market continues to rapidly evolve, so it is important for all healthcare practitioners to be equally adept in their management of healthcare delivery as in their practice of medicine. A recent book by Toby Cosgrove MD, the CEO and president of the Cleveland Clinic, offers exquisite insight into transforming the institution’s healthcare delivery and outcomes to meet the 21...